[go: up one dir, main page]

MA50670A - Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose - Google Patents

Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose

Info

Publication number
MA50670A
MA50670A MA050670A MA50670A MA50670A MA 50670 A MA50670 A MA 50670A MA 050670 A MA050670 A MA 050670A MA 50670 A MA50670 A MA 50670A MA 50670 A MA50670 A MA 50670A
Authority
MA
Morocco
Prior art keywords
antibody compositions
new formulations
dose antibody
stabilize low
stabilize
Prior art date
Application number
MA050670A
Other languages
English (en)
Inventor
Joanna Mackay
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA50670A publication Critical patent/MA50670A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D65/00Wrappers or flexible covers; Packaging materials of special type or form
    • B65D65/38Packaging materials of special type or form
    • B65D65/42Applications of coated or impregnated materials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA050670A 2017-09-29 2018-09-28 Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose MA50670A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762565178P 2017-09-29 2017-09-29

Publications (1)

Publication Number Publication Date
MA50670A true MA50670A (fr) 2020-08-05

Family

ID=65896542

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050670A MA50670A (fr) 2017-09-29 2018-09-28 Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose

Country Status (5)

Country Link
US (2) US20190099489A1 (fr)
EP (1) EP3688033A4 (fr)
JP (1) JP2020535181A (fr)
MA (1) MA50670A (fr)
WO (1) WO2019064263A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
TW202104269A (zh) 2019-04-23 2021-02-01 法商賽諾菲公司 抗cd38抗體和調配物
JP2022552396A (ja) * 2019-10-16 2022-12-15 ヤンセン ファッシンズ アンド プリベンション ベーフェー ワクチン製品
AU2020370372A1 (en) * 2019-10-25 2022-05-12 Amgen Inc. Compositions and methods for minimizing protein loss at low protein concentrations
BR112022013730A2 (pt) * 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
JP2024511154A (ja) * 2021-03-25 2024-03-12 ショット ファーマ アクチェンゲゼルシャフト ウント コンパニー コマンディートゲゼルシャフト アウフ アクチェン 医薬品用の容器

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19921303C1 (de) * 1999-05-07 2000-10-12 Schott Glas Glasbehälter für medizinische Zwecke
WO2001017542A1 (fr) * 1999-09-08 2001-03-15 Chugai Seiyaku Kabushiki Kaisha Preparation de solution de proteines et procede de stabilisation associe
US8025915B2 (en) * 2006-01-11 2011-09-27 Schott Ag Method of preparing a macromolecule deterrent surface on a pharmaceutical package
EP1988922A4 (fr) * 2006-02-03 2010-06-02 Medimmune Llc Formulations de protéines
CN101889209A (zh) * 2007-10-22 2010-11-17 贝克顿·迪金森公司 评价在含有机基聚硅氧烷的悬浮液中蛋白质聚集的方法和用含蛋白质溶液的有机基聚硅氧烷涂布的医疗制品
JP2014500879A (ja) * 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Bcma発現に相関性を有する疾患を治療する因子及び方法
WO2013179514A1 (fr) * 2012-05-28 2013-12-05 株式会社ナミコス Récipient de verre, et procédé de fabrication de celui-ci
RU2019120404A (ru) * 2013-03-13 2019-08-06 Дженентек, Инк. Составы антител
TW201501724A (zh) * 2013-03-15 2015-01-16 Glaxosmithkline Ip No 2 Ltd 低濃度抗體調配物
CN104057880B (zh) * 2014-07-09 2016-04-06 郑运婷 车门防撞装置
WO2016048938A1 (fr) * 2014-09-26 2016-03-31 Macrogenics, Inc. Anticorps dimériques monovalents bispécifiques à région capables de se lier à cd19 et à cd3 et leurs utilisations

Also Published As

Publication number Publication date
EP3688033A1 (fr) 2020-08-05
JP2020535181A (ja) 2020-12-03
US20190099489A1 (en) 2019-04-04
WO2019064263A1 (fr) 2019-04-04
US20220202937A1 (en) 2022-06-30
EP3688033A4 (fr) 2021-06-23

Similar Documents

Publication Publication Date Title
MA50670A (fr) Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
CY1122718T1 (el) Σκευασμα συνδυασμου δυο αντι-ιικων ενωσεων
EP3548000A4 (fr) Compositions pharmaceutiques d'atropine
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
EP3256149A4 (fr) Formulations pour administration orale d'agents actifs
EP3353213A4 (fr) Nouvel anticorps anti-mésothéline et composition le comprenant
EP3656821A4 (fr) Composition d'asphalte
EP3412344A4 (fr) Composition d'agent extincteur
EP2962698A4 (fr) Composition pharmaceutique comprenant un facteur migratoire destiné à guider des cellules souches pluripotentes jusqu'à une blessure
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA54052A (fr) Formulation d'anticorps
MA53466A (fr) Formulation stable d'anticorps anti-osmr
MA56049A (fr) Formulations stabilisées contenant des anticorps anti-angptl3
MA54139A (fr) Formulation d'anticorps
EP3720597C0 (fr) Compositions macromoléculaires comprenant des dérivés d'indène
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
MA55362A (fr) Formulations stabilisées contenant des anticorps anti-il-33
EP3349755A4 (fr) Formulations de nicotine, leurs procédés de préparation et d'utilisation
MA55033A (fr) Formulation d'anticorps thérapeutique
MA45451A (fr) Formulations tensioactives destinées à l'inhalation
EP3394099A4 (fr) Formulations d'anticorps anti-il-10 modifiés
EP3463259A4 (fr) Compositions d'écran solaire
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen